• Acute Care
    Medicure achieved a ranking as
    A 2016 TSX Venture 50 Company
  • Acute Care
    Medicure Focuses On
    Acute Care
    Hospital Products
  • Aggrastat HDB FDA Approved
    FDA APPROVES
    Aggrastat HDB
    The high-dose bolus (HDB) dosing regimen has been added to the Aggrastat (tirofiban HCI) Prescribing Information.
  • Medicure Investments
    medicure is traded
    on TSX Venture (MPH)
    The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban HCI).

Annual and Special Meeting of the Shareholders of Medicure Inc.

held in Winnipeg, Manitoba, at 2-1250 Waverley Street

Wednesday June 22, 2016 at 10:00 a.m. (Central Daylight time)

Aggrastat

Aggrastat® is Medicure's leading speciality pharmaceutical product.

Aggrastat